Keyphrases
Aminotransferase
9%
Beneficial Effects
9%
Caspase
9%
Child-Pugh Score
9%
Cirrhosis
100%
Cirrhosis Complications
9%
Clinical Outcomes
9%
Clinical Trials
18%
Cytokeratin
9%
Double-blinded Study
9%
Emricasan
100%
Experimental Cirrhosis
9%
Gradient Compensation
9%
Hepatic Venous Pressure Gradient
100%
High Pressure
9%
Inflammation
9%
Lay Summary
9%
Liver
18%
Liver Outcomes
9%
MELD Score
9%
No Significant Difference
9%
Non-associated
9%
Nonalcoholic Steatohepatitis
100%
Nonselective β-blockers
9%
Number of Trials
9%
Pan-caspase Inhibitor
9%
Placebo
27%
Placebo-controlled Study
9%
Portal Pressure
27%
Portal Vein
9%
Randomized Placebo-controlled Trial
100%
Scar
18%
Severe Portal Hypertension
100%
Target Engagement
9%
Treatment Effect
9%
Treatment Group
9%
Treatment-related Adverse Events
9%
Twice Daily
9%
Medicine and Dentistry
Adverse Event
9%
Beta Adrenergic Receptor Blocking Agent
9%
Biological Marker
27%
Caspase
9%
Caspase Inhibitor
9%
Cefaclor
9%
Child-Pugh Score
9%
Clinical Trial
18%
Cytokeratin
9%
Emricasan
100%
Group Therapy
9%
Hepatic Portal Vein
9%
Hyperbarism
9%
Liver Cirrhosis
100%
Model for End-Stage Liver Disease
9%
Nonalcoholic Fatty Liver
100%
Placebo
100%
Placebo-Controlled Study
9%
Portal Hypertension
100%
Portal Venous Pressure
27%
Scar Formation
18%
Transaminase
9%
Treatment Effect
9%
Venous Pressure
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Aminotransferase
9%
Beta Adrenergic Receptor Blocking Agent
9%
Biological Marker
27%
Caspase
9%
Caspase Inhibitor
9%
Cefaclor
9%
Clinical Trial
18%
Cytokeratin
9%
Emricasan
100%
End Stage Liver Disease
9%
Hyperbarism
9%
Inflammation
9%
Liver Cirrhosis
100%
Nonalcoholic Fatty Liver
100%
Placebo
100%
Placebo-Controlled Study
9%
Portal Hypertension
100%
Scar Formation
18%